[1] 郭真, 严梦寒, 翁璐昕, 等. 彩超联合CT对甲状腺乳头状癌颈部微小转移淋巴的应用[J]. 中国CT和MRI杂志, 2020, 18(4): 33. doi: 10.3969/j.issn.1672-5131.2020.04.011
[2] 于婧, 王凤琴, 姚文娟, 等. BRAFV600E基因突变与甲状腺乳头状癌中央区淋巴结转移的关系[J]. 蚌埠医学院学报, 2020, 45(4): 493.
[3] SCHWERTHEIM S, THEURER S, JASTROW H, et al. New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation[J]. PLoS One, 2019, 14(12): e0226199. doi: 10.1371/journal.pone.0226199
[4] 王文勇, 黄晓峰, 王映梅, 等. 免疫组化技术标准化的探讨[J]. 细胞与分子免疫学杂志, 2011, 27(8): 927.
[5] HIROKAWA T, ARIMASU Y, CHIBA T, et al. Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma[J]. Pathol Int, 2020, 70(4): 217. doi: 10.1111/pin.12900
[6] GAN X, SHEN F, DENG X, et al. Prognostic implications of the BRAF-V600E mutation in papillary thyroid carcinoma based on a new cut-off age stratification[J]. Oncol Lett, 2020, 19(1): 631.
[7] ZATELLI MC, TRASFORINI G, LEONI S, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies[J]. Eur J Endocrinol, 2009, 161(3): 467. doi: 10.1530/EJE-09-0353
[8] 刘欣迪, 周青, 朱远, 等. 甲状腺乳头状癌患者首次131 I治疗前刺激性Tg与TSH比值与最佳治疗反应的关系[ J]. 现代肿瘤医学, 2020, 28(10): 1646. doi: 10.3969/j.issn.1672-4992.2020.10.008
[9] BASTOS AU, OLER G, NOZIMA BH, et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma[J]. Eur J Endocrinol, 2015, 173(4): 525. doi: 10.1530/EJE-15-0254
[10] 王萍. 甲状腺乳头状癌中BRAFT1799A基因突变与TGF-β的关联及对肿瘤预后的影响[D]. 青岛: 青岛大学, 2017: 1.
[11] 高卫利. 在甲状腺乳头状癌中BRAF ~ (V600E)基因突变和NIS蛋白的表达及其临床意义[D]. 杭州: 浙江大学, 2012.
[12] 茹晓婷, 刘勤江, 杨荣. NIS和TSHR在分化型甲状腺癌中的表达及其与BRAFV600E突变的关系研究[ J]. 临床肿瘤学杂志, 2017, 22(2): 128.